Ignite Creation Date:
2024-05-06 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03417882
Status:
TERMINATED
Last Update Posted:
2023-08-08
First Post:
2017-11-14
Brief Title:
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1 NSCLC
Sponsor:
BrightPath Biotherapeutics
Organization:
BrightPath Biotherapeutics
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-01-03
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-05
Completion Date Type:
ACTUAL
First Submit Date:
2017-11-14
First Submit QC Date:
January 30 2018
Study First Post Date:
2018-01-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-05
Last Update Post Date:
2023-08-08
Last Update Post Date Type:
ACTUAL